{rfName}
Pe

Indexed in

License and Use

Icono OpenAccess

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Sampedro-Nuñez M.Authorálvarez-Escolá C.AuthorMarazuela, MonicaAuthor

Share

December 4, 2025
Publications
>
Article
Hybrid Gold

Personalized Medicine in Acromegaly: The ACROFAST Study

Publicated to: Journal Of Clinical Endocrinology & Metabolism. 110 (1): 30-40 - 2025-01-01 110(1), DOI: 10.1210/clinem/dgae444

Authors:

Marques-Pamies, Montserrat; Gil, Joan; Sampedro-Nunez, Miguel; Valassi, Elena; Biagetti, Betina; Gimenez-Palop, Olga; Hernandez, Marta; Martinez, Silvia; Carrato, Cristina; Villar-Taibo, Rocio; Araujo-Castro, Marta; Blanco, Concepcion; Simon-Muela, Inmaculada; Simo-Servat, Andreu; Xifra, Gemma; Vazquez, Federico; Pavon, Isabel; Rosado, Jose Antonio; Garcia-Centeno, Rogelio; Zavala, Roxana; Hanzu, Felicia Alexandra; Mora, Mireia; Aulinas, Anna; Vilarrasa, Nuria; Librizzi, Soledad; Calatayud, Maria; de Miguel, Paz; Alvarez-Escola, Cristina; Pico, Antonio; Salinas, Isabel; Fajardo-Montanana, Carmen; Camara, Rosa; Bernabeu, Ignacio; Jorda, Mireia; Webb, Susan M; Marazuela, Monica; Puig-Domingo, Manel
[+]

Affiliations

12 Octubre Univ Hosp, Dept Endocrinol & Nutr, Madrid 28041, Spain - Author
Arnau de Vilanova Univ Hosp, Dept Endocrinol & Nutr, Lleida 25198, Spain - Author
Bellvitge Univ Hosp, Dept Endocrinol & Nutr, Lhospitalet De Llobregat 08907, Spain - Author
Clin San Carlos Univ Hosp, Dept Endocrinol & Nutr, Madrid 2546, Spain - Author
Clin Santiago Univ Hosp, Dept Endocrinol & Nutr, Santiago De Compostela 15706, Spain - Author
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Inst Salud Carlos III ISCIII, Unidad 747, Barcelona 28029, Spain - Author
Dr Pifarre Fdn IRBLleida, Lleida Inst Biomed Res, Endocrine Res Unit, Lleida 25198, Spain - Author
Germans Trias i Pujol Res Inst IGTP, Endocrine Res Unit, Badalona 08916, Spain - Author
Germans Trias i Pujol Univ Hosp, Dept Endocrinol & Nutr, Badalona 08916, Spain - Author
Germans Trias i Pujol Univ Hosp, Dept Hormonal Lab, Badalona 08916, Spain - Author
Germans Trias i Pujol Univ Hosp, Dept Pathol, Badalona 08916, Spain - Author
Getafe Univ Hosp, Dept Endocrinol & Nutr, Madrid 28905, Spain - Author
Gregorio Maranon Univ Hosp, Dept Endocrinol & Nutr, Madrid 28007, Spain - Author
Hosp Clin Univ Hosp, Dept Endocrinol & Nutr, Barcelona 08036, Spain - Author
Hosp Municipal Badalona, Dept Endocrinol & Nutr, Badalona 08911, Spain - Author
Hosp Santa Creu & Sant Pau, Inst Recerca St Pau IIB St Pau, Res Ctr Pituitary Dis, Dept Endocrinol & Nutr, Barcelona 08041, Spain - Author
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Endocrine Res Unit, Barcelona 08036, Spain - Author
Inst Invest Biomed Bellvitge IDIBELL, Endocrine Res Unit, Lhospitalet De Llobregat 08907, Spain - Author
Inst Invest Ramon y Cajal IRYCIS, Madrid 28034, Spain - Author
Inst Invest Sanit & Biomed Alicante ISABIAL, Endocrine Res Unit, Alicante 03010, Spain - Author
Inst Invest Sanit Pere Virgili IISPV, Endocrine Res Unit, Tarragona 43005, Spain - Author
Inst Salud Carlos III ISCIII, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid 28029, Spain - Author
Joan XXIII Univ Hosp, Dept Endocrinol & Nutr, Tarragona 43005, Spain - Author
Josep Trueta Univ Hosp, Dept Endocrinol & Nutr, Girona 17007, Spain - Author
La Fe Univ Hosp, Dept Endocrinol & Nutr, Valencia 46026, Spain - Author
La Paz Univ Hosp, Dept Endocrinol & Nutr, Madrid 28046, Spain - Author
La Princesa Univ Hosp, Dept Endocrinol & Nutr, Madrid 28006, Spain - Author
La Ribera Univ Hosp, Dept Endocrinol & Nutr, Valencia 46600, Spain - Author
Miguel Hernandez Univ, Gen Univ Hosp Dr Balmis, Dept Endocrinol & Nutr, Alicante 03010, Spain - Author
Mutua de Terrassa Univ Hosp, Dept Endocrinol & Nutr, Terrassa 08221, Spain - Author
Parc Tauli Univ Hosp, Dept Endocrinol & Nutr, Sabadell 08208, Spain - Author
Principe Asturias Univ Hosp, Dept Endocrinol & Nutr, Madrid 28805, Spain - Author
Ramon y Cajal Univ Hosp, Dept Endocrinol & Nutr, Madrid 28034, Spain - Author
Rovira i Virgili Univ URV, Tarragona 43003, Spain - Author
Univ Autonoma Barcelona UAB, Dept Med, Bellaterra 08193, Spain - Author
Vall Hebron Univ Hosp, Dept Endocrinol & Nutr, Barcelona 08035, Spain - Author
See more

Abstract

Context: Medical treatment of acromegaly is currently performed through a trial-and-error approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs, with an effectiveness of about 50%, and subsequent drugs are indicated through clinical judgment. Some biomarkers can predict fgSRLs response. Objective: Here we report the results of the ACROFAST study, a clinical trial in which a protocol based on predictive biomarkers of fgSRLs was evaluated. Methods: This was a prospective trial (21 university hospitals) comparing the effectiveness and time-to-control of 2 treatment protocols during 12 months: (A) a personalized protocol in which the first options were fgSRLs as monotherapy or in combination with pegvisomant, or pegvisomant as monotherapy depending on the short acute octreotide test (sAOT) results, tumor T2 magnetic resonance (MRI) signal or immunostaining for E-cadherin; and (B) a control group with treatment always started by fgSRLs and the other drugs included after demonstrating inadequate control. Results: Eighty-five patients participated; 45 in the personalized and 40 in the control group. More patients in the personalized protocol achieved hormonal control compared to those in the control group (78% vs 53%, P < .05). Survival analysis revealed a hazard ratio for achieving hormonal control adjusted by age and sex of 2.53 (CI, 1.30-4.80). Patients from the personalized arm were controlled in a shorter period of time (P = .01). Conclusion: Personalized medicine is feasible using a relatively simple protocol, and it allows a higher number of patients to achieve control in a shorter period of time.
[+]

Keywords

AcromegalyAcute octreotide testBiochemical responseClinical trialExpressionFirst-generation somatostatin receptor ligandsGood health and well-beingHormoneMedical treatmentMortalityPersonalized therapyPredictionQuality-of-lifeSomatostatin analogsSubtypesT2-weighted mriTherapeutic response prediction

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal of Clinical Endocrinology & Metabolism due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2025, it was in position 36/193, thus managing to position itself as a Q1 (Primer Cuartil), in the category Endocrinology & Metabolism.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-05:

  • Open Alex: 2
  • WoS: 12
  • Scopus: 14
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-05:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 23.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 23 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 59.
  • The number of mentions on the social network X (formerly Twitter): 29 (Altmetric).
  • The number of mentions in news outlets: 6 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
  • Assignment of a Handle/URN as an identifier within the deposit in the Institutional Repository: https://repositorio.uam.es/handle/10486/714746
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 3 - Ensure healthy lives and promote well-being for all at all ages, with a probability of 84% according to the mBERT algorithm developed by Aurora University.
[+]

Awards linked to the item

This research was funded by the Instituto de Salud Carlos III grant PMP15/00027, co-funded by the European Regional Development Fund - European Union; and PMP22/00021, funded by the European Union-NextGenerationEU, both to Manel Puig-Domingo, and partially supported by the Spanish Society of Endocrinology and Nutrition.
[+]